AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28325472 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) interstitial brachytherapy with one fraction of 19 Gy
Number of subjects: 87
Study 28325472 — intervention group
Group type: COMPARATOR
Intervention: Low-dose-rate (LDR) interstitial brachytherapy with 145 Gy
Number of subjects: 87
Study 26684872 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical and Mental Health Unit (MMHU)
Number of subjects: 600
Study 26684872 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 600
Study 26684872 — intervention group
Group type: EXPERIMENTAL
Intervention: MMHU
Number of subjects: 600
Study 23194084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 1 mg/day
Number of subjects: 279
Study 23194084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg/day
Number of subjects: 279
Study 23194084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg/day
Number of subjects: 279
Study 23194084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 279
Study 23194084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (1, 2.5, 5, or 10 mg/day)
Number of subjects: 279
Study 23194084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 21252308 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking at systematically increased speeds
Number of subjects: 20
Study 21252308 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking at self-selected speed
Number of subjects: 20
Study 18471631 — intervention group
Group type: EXPERIMENTAL
Intervention: AF‐1 (UY) IOL (blue-light-filtering)
Number of subjects: 2
Study 18471631 — intervention group
Group type: COMPARATOR
Intervention: AF‐1 (UV) IOL (clear)
Number of subjects: 2
Study 16542747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m² on day 1 and gemcitabine 1,200 mg/m² on days 1 and 8, every 3 weeks for four courses (CG regimen)
Number of subjects: 54
Study 16542747 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 10 mg/m² on day 1, methotrexate 35 mg/m² on day 1, and mitomycin 7 mg/m² on day 1, every 3 weeks with mitomycin in alternate cycles for four courses (MMM regimen)
Number of subjects: 54
Study 14515196 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg prinomastat plus gemcitabine/cisplatin (GC)
Number of subjects: 1023
Study 14515196 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg prinomastat plus paclitaxel/carboplatin (PC)
Number of subjects: 1023
Study 14515196 — intervention group
Group type: COMPARATOR
Intervention: 15 mg prinomastat alone (post‐discontinuation of chemotherapy)
Number of subjects: 1023
Study 14515196 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus placebo
Number of subjects: 1023
Study 14515196 — intervention group
Group type: COMPARATOR
Intervention: 5 or 10 mg prinomastat plus chemotherapy
Number of subjects: 1023
Study 14515196 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheter placed within 3 months
Number of subjects: 1023
Study 11198727 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin ethyl succinate
Number of subjects: 73
Study 11198727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 9254871 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal invitation letter for a routine mammogram at a specific time
Number of subjects: 1500
Study 9254871 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation letters (4 different styles)
Number of subjects: 1500
Study 9254871 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical breast examination within the previous year
Number of subjects: 1500
Study 9254871 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation from a health professional for routine mammography
Number of subjects: 1500
Study 9254871 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of mammography as efficient in early detection of breast cancer
Number of subjects: 1500
Study 9254871 — intervention group
Group type: COMPARATOR
Intervention: Aggressiveness of message details or signature from a family physician or higher authority
Number of subjects: 1500
Study 8483865 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in genetic testing for colon cancer susceptibility
Number of subjects: 401
Study 8483865 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risk for colon cancer
Number of subjects: 401
Study 8483865 — intervention group
Group type: COMPARATOR
Intervention: Different question frames
Number of subjects: 401
Study 2935242 — intervention group
Group type: EXPERIMENTAL
Intervention: IA FUDR (0.3‐0.1 mg/kg/day X 14, every 28 days)
Number of subjects: 86
Study 2935242 — intervention group
Group type: COMPARATOR
Intervention: IV FUDR (0.05‐0.15 mg/kg/day X 14, every 28 days)
Number of subjects: 86
Study 30203481 — intervention group
Group type: EXPERIMENTAL
Intervention: Galaxy Rescuers game (game-only group)
Number of subjects: 328
Study 30203481 — intervention group
Group type: EXPERIMENTAL
Intervention: Galaxy Rescuers game (game-with-debriefing group)
Number of subjects: 328
Study 30203481 — intervention group
Group type: EXPERIMENTAL
Intervention: Game satisfaction survey
Number of subjects: 328
Study 27733522 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate (7 mg/kg body weight)
Number of subjects: 20
Study 27733522 — intervention group
Group type: COMPARATOR
Intervention: Potassium chloride (placebo)
Number of subjects: 20
Study 1578948 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐day courses of ARA‐C plus thioguanine
Number of subjects: 0
Study 1578948 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ARA‐C (HDARAC) plus Asparaginase
Number of subjects: 0
Study 1578948 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin or Daunorubicin in combination with Cytarabine in a standard 3+7 protocol
Number of subjects: 0
Study 1578948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose ARA‐A (IDARAC) plus Mitoxantrone
Number of subjects: 0
Study 1578948 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative treatment with Thioguanine and ARA‐C
Number of subjects: 0
Study 22782949 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 µg adjuvanted vaccine
Number of subjects: 789
Study 22782949 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 µg adjuvanted vaccine
Number of subjects: 789
Study 22782949 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 µg adjuvanted vaccine
Number of subjects: 789
Study 22782949 — intervention group
Group type: COMPARATOR
Intervention: 15 µg unadjuvanted vaccine
Number of subjects: 789
Study 20075020 — intervention group
Group type: EXPERIMENTAL
Intervention: TETRA base station signal
Number of subjects: 183
Study 20075020 — intervention group
Group type: COMPARATOR
Intervention: Sham (no signal)
Number of subjects: 183
Study 19124357 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol 50 microg QD
Number of subjects: 793
Study 19124357 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 42 microg BID
Number of subjects: 793
Study 15817866 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula supplemented with DHA (0.36%) and ARA (0.72%)
Number of subjects: 103
Study 15817866 — intervention group
Group type: COMPARATOR
Intervention: Control formula with no DHA or ARA
Number of subjects: 103
Study 12502678 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 15
Study 12502678 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular human insulin
Number of subjects: 15
Study 12502678 — intervention group
Group type: COMPARATOR
Intervention: No insulin
Number of subjects: 15
Study 10232178 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer months (May to July)
Number of subjects: 40
Study 10232178 — intervention group
Group type: EXPERIMENTAL
Intervention: School months (August to October)
Number of subjects: 40
Study 10232178 — intervention group
Group type: COMPARATOR
Intervention: Lack of consistency in summer routines
Number of subjects: 40
Study 10232178 — intervention group
Group type: COMPARATOR
Intervention: Lower guidance scores on the Diabetes Family Behavior Scale
Number of subjects: 40
Study 10232178 — intervention group
Group type: COMPARATOR
Intervention: Higher impact and worry scores on the Diabetes Quality of Life for Youth Scale
Number of subjects: 40
Study 8746180 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluoridation with 2% NaF solution before orthodontic band cementation with zinc phosphate cement
Number of subjects: 21
Study 8746180 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic band cementation with glass ionomer cement
Number of subjects: 21
Study 8746180 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dental procedures)
Number of subjects: 21
Study 2736431 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 8.8 mg
Number of subjects: 12
Study 2736431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 798330 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous methylprednisolone therapy at the time of kidney transplantation
Number of subjects: 45
Study 31567176 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-sparing diuretics (e.g., spironolactone)
Number of subjects: 168
Study 30841856 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible non-linear models within the Prentice framework
Number of subjects: 0
Study 30841856 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalized likelihood approaches
Number of subjects: 0
Study 28522338 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Number of subjects: 3693
Study 28522338 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 3693
Study 25386713 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.1 g·kg·d) during resistance training
Number of subjects: 47
Study 25386713 — intervention group
Group type: COMPARATOR
Intervention: Placebo during resistance training
Number of subjects: 47
Study 24353047 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100‐250 mg bid)
Number of subjects: 2968
Study 24353047 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone HCl CR (20‐50 mg)
Number of subjects: 2968
Study 24353047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2968
Study 21530799 — intervention group
Group type: EXPERIMENTAL
Intervention: NO dietary supplement Neo40 Daily®
Number of subjects: 0
Study 21530799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18427723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (oral, ≤3 mg once daily for 76 weeks)
Number of subjects: 115
Study 18427723 — intervention group
Group type: COMPARATOR
Intervention: Mizoribine (previous treatment)
Number of subjects: 115
Study 22089267 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ibuprofen (20-10-10 mg/kg/day)
Number of subjects: 70
Study 22089267 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose ibuprofen (10-5-5 mg/kg/day)
Number of subjects: 70
Study 15764851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 0
Study 15764851 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 0
Study 12446161 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric phase of arm elevation at 100 degrees
Number of subjects: 52
Study 12446161 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric phase of arm elevation at 120 degrees
Number of subjects: 52
Study 12446161 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric phase at 80 degrees
Number of subjects: 52
Study 12446161 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric phase at 100 degrees
Number of subjects: 52
Study 12446161 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric phase at 120 degrees
Number of subjects: 52
Study 12446161 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic group compared to healthy group
Number of subjects: 52
Study 9648050 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC 01-0687 (dopamine D1 antagonist)
Number of subjects: 8
Study 9648050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8054328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol
Number of subjects: 10
Study 8054328 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomalt
Number of subjects: 10
Study 8054328 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 10
Study 2645016 — intervention group
Group type: EXPERIMENTAL
Intervention: Angelchik prosthesis
Number of subjects: 61
Study 2645016 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication
Number of subjects: 61
Study 824215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (DZ)
Number of subjects: 33
Study 824215 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 33
Study 29227351 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS block with 30 ml of levobupivacaine 0.25% after induction of anaesthesia
Number of subjects: 60
Study 29227351 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS block with propofol-remifentanil anaesthesia
Number of subjects: 60
Study 29227351 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS block
Number of subjects: 60
Study 29227351 — intervention group
Group type: COMPARATOR
Intervention: Saline mock block (Control group)
Number of subjects: 60
Study 27727281 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telecoaching program
Number of subjects: 574
Study 25245591 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial random noise stimulation (tRNS) over auditory cortex, 20 min, 2 mA
Number of subjects: 14
Study 25245591 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham stimulation)
Number of subjects: 14
Study 22639988 — intervention group
Group type: EXPERIMENTAL
Intervention: Welfare rights advice service
Number of subjects: 750
Study 22639988 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 750
Study 20545689 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (DS) containing Lactobacillus johnsonii (La1) and carotenoids for 10 weeks
Number of subjects: 139
Study 17881390 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) treatment
Number of subjects: 58
Study 17881390 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 58
Study 15778071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led (protocol-directed) weaning
Number of subjects: 7
Study 15778071 — intervention group
Group type: COMPARATOR
Intervention: Medical-led weaning
Number of subjects: 7
Study 12089891 — intervention group
Group type: COMPARATOR
Intervention: Captopril (C)
Number of subjects: 93
Study 9974369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - nadroparin, 85 anti-Xa IU/kg s.c. once daily
Number of subjects: 202
Study 9974369 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulant (OA) - acenocoumarol
Number of subjects: 202
Study 7673609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 4 weeks, followed by famotidine 20 mg twice daily for 4 weeks
Number of subjects: 54
Study 7673609 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 20 mg twice daily for 4 weeks, followed by lansoprazole 30 mg once daily for 4 weeks
Number of subjects: 54
Study 7673609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole after switching from famotidine
Number of subjects: 54
Study 7673609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 54
Study 7673609 — intervention group
Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 54
Study 2206878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVGG) 800 mg/kg
Number of subjects: 10
Study 2206878 — intervention group
Group type: COMPARATOR
Intervention: Intravenous albumin
Number of subjects: 10
Study 7193003 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation A (Acetylsalicylic acid + glycine)
Number of subjects: 20
Study 7193003 — intervention group
Group type: COMPARATOR
Intervention: Test preparation B (Microencapsulated Acetylsalicylic acid)
Number of subjects: 20
Study 7193003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ASA preparations (1000 mg ASA)
Number of subjects: 20
Study 7193003 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation A
Number of subjects: 20
Study 7193003 — intervention group
Group type: COMPARATOR
Intervention: Test preparation B
Number of subjects: 20
Study 31809479 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 4728
Study 31809479 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin plus GPI
Number of subjects: 4728
Study 31809479 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus GPI
Number of subjects: 4728
Study 31809479 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-positive patients
Number of subjects: 4728
Study 31132105 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized meal (5025 kJ)
Number of subjects: 18
Study 31132105 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 18
Study 28789492 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin (5 mg/d)
Number of subjects: 1421
Study 28789492 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1421
Study 25808394 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin CR 330 mg alone
Number of subjects: 18
Study 25808394 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin CR 330 mg co-administered with erythromycin 500 mg
Number of subjects: 18
Study 23660206 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 446
Study 23660206 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher white blood cell count (WBC)
Number of subjects: 446
Study 23660206 — intervention group
Group type: EXPERIMENTAL
Intervention: History of alcohol drinking
Number of subjects: 446
Study 23660206 — intervention group
Group type: EXPERIMENTAL
Intervention: High National Institute of Health stroke scale (NIHSS score)
Number of subjects: 446
Study 23660206 — intervention group
Group type: EXPERIMENTAL
Intervention: High total cholesterol (TC)
Number of subjects: 446
Study 21421955 — intervention group
Group type: EXPERIMENTAL
Intervention: COACH intervention (Web-based risk assessments with personal coaching support)
Number of subjects: 423
Study 21421955 — intervention group
Group type: EXPERIMENTAL
Intervention: RealAge intervention (Web-based risk assessment and behavior-specific modules)
Number of subjects: 423
Study 21421955 — intervention group
Group type: COMPARATOR
Intervention: Control group (printed health-promotion materials)
Number of subjects: 423
Study 19535722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary block
Number of subjects: 0
Study 19535722 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0
Study 17891901 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot environment (39 degrees C; RH 30%)
Number of subjects: 8
Study 17891901 — intervention group
Group type: COMPARATOR
Intervention: Cold environment (9 degrees C; RH 61%)
Number of subjects: 8
Study 12639353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microg/kg IV
Number of subjects: 100
Study 12639353 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 1 mg/kg IM
Number of subjects: 100
Study 12639353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg/kg IM
Number of subjects: 100
Study 12639353 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic mixture local anesthetic (EMLA) cream 15 g
Number of subjects: 100
Study 10674777 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics (risperidone, olanzapine)
Number of subjects: 0
Study 10674777 — intervention group
Group type: COMPARATOR
Intervention: Risperidone, Olanzapine
Number of subjects: 0
Study 10674777 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 0
Study 10674777 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 10674777 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0
Study 8956371 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase (F)
Number of subjects: 15
Study 8956371 — intervention group
Group type: COMPARATOR
Intervention: Menstrual phase (M)
Number of subjects: 15
Study 8956371 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase (L)
Number of subjects: 15
Study 1610929 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 798
Study 1610929 — intervention group
Group type: COMPARATOR
Intervention: Iopromide
Number of subjects: 798
Study 3889748 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (2 g intravenously every eight hours) with clindamycin (600 mg intravenously every six hours)
Number of subjects: 119
Study 3889748 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (1.5 mg/kg intravenously every eight hours) with clindamycin (600 mg intravenously every six hours)
Number of subjects: 119
Study 3889748 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (600 mg intravenously every six hours)
Number of subjects: 119
Study 30799637 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid
Number of subjects: 0
Study 30799637 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare or no insurance
Number of subjects: 0
Study 30799637 — intervention group
Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 0
Study 30799637 — intervention group
Group type: COMPARATOR
Intervention: Private insurance
Number of subjects: 0
Study 29320646 — intervention group
Group type: COMPARATOR
Intervention: Frozen-embryo transfer
Number of subjects: 2157
Study 29320646 — intervention group
Group type: COMPARATOR
Intervention: Fresh-embryo transfer
Number of subjects: 2157
Study 27769273 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicating individual BRCA results
Number of subjects: 0
Study 27769273 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregate BRCA result communication
Number of subjects: 0
Study 25315204 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 62
Study 25315204 — intervention group
Group type: COMPARATOR
Intervention: Gastric banding (GB)
Number of subjects: 62